Based on the results presented in this paper, we speculated that SMYD3 might induce MDR phenotype by promoting the glycolysis of DLBCL cells, which provided more ATP for drug efflux transporters and increased acidification of the tumor microenvironment in favor of the catalytic activity of the efflux transporter [38, 39]. The gene discussed is SMYD3; the disease is diffuse large B-cell lymphoma.